Symposia & Webinars
Broader usage of combinations in daily clinical practice: what benefits for patients?
Alberto Zambon speaks about the management of dyslipidemia with combination therapies, across different topics:
- Expected clinical benefits of LDL-C lowering therapies
- Euroaspire surveys IV-V
- Patterns of statin use in a real-world population of patients at high CV risk
- Results of a meta-analysis of 8 statin trials
- Efficacy of ezetimibe in lowering LDL-C vs doubling dose of statin in high risk previously treated statin patients: systematic review and networks meta-analysis
- Pattern of statin use in a real-world population of patients at high cardiovascular risk
- Association of combined measure of adherence and treatment intensity with cardiovascular outcomes in patients with atherosclerosis or other cardiovascular risk factors treated with statins and/or ezetimibe
The presentation closes with results about adherence to statin therapy in patients hospitalized for ACS at the Padua University Hospital.
This video is part of the session “Choosing the best treatment approach to dyslipidemia: monotherapy vs combination therapy” held virtually at ESC congress 2020 on Monday August 31st, 2020, with co-chairs A. Zambon and L. Perez de Isla.
View also the other parts of the congress session: